Search
Diffuse Large B-Cell Lymphoma Clinical Trials in Canada
A listing of 10 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 10 of 10
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Diffuse Large B-Cell Lymphoma
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
There are currently 10 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are .
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Recruiting
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: City of Hope Cancer Center, Duarte, California +173 locations
City of Hope Cancer Center, Duarte, California
University of California San Diego Medical Center, La Jolla, California
University of California Los Angeles, Los Angeles, California
St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California
Stanford University Medical Center, Stanford, California
Stanford University, Stanford, California
Norwalk Medical Group, Norwalk, Connecticut
Northwest Georgia Oncology Centers PC, Marietta, Georgia
Northwestern University Hospital, Chicago, Illinois
Indiana University, Goshen, Indiana
Kansas University Medical Center, Westwood, Kansas
Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky
Dana Farber Cancer Center, Boston, Massachusetts
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Battle Creek Health Systm, Battle Creek, Michigan
Karmanos Cancer Institute - Wayne State University, Detroit, Michigan
Washington University, Saint Louis, Missouri
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Hackensack University Medical Center, Hackensack, New Jersey
Weill Medical College of Cornell University, New York, New York
Memorial Sloan-Kettering Cancer Center, New York, New York
Southeastern Medical Oncology Center, Goldsboro, North Carolina
The Ohio State University- James Cancer Hospital, Columbus, Ohio
Willamette Valley Cancer Center, Eugene, Oregon
Kaiser Permanente, Portland, Oregon
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Avera Medical Group, Sioux Falls, South Dakota
MD Anderson Cancer Center - University of Texas, Houston, Texas
University of Virginia, Charlottesville, Virginia
University of Washington, Seattle, Washington
West Virginia University, Morgantown, West Virginia
University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin
CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Not set
Fundaleu, Ciudad de Buenos Aires, Not set
Royal Adelaide Hospital, Adelaide, Not set
John Fawkner Cancer Trial Centre, Coburg, Not set
Concord Hospital, Concord, Not set
Austin Health, Heidelberg, Not set
Peter MacCallum Cancer Institute, Melbourne, Not set
Royal Perth Hospital, Perth, Not set
Alfred Hospital, Prahran, Not set
Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga, Not set
UZA, Antwerp, Not set
A.Z. Sint Jan, Brugge, Not set
UCL - Saint Luc, Brussels, Not set
UZ Gent - departement oncologie, Gent, Not set
UZ Leuven Gasthuisberg, Leuven, Not set
UCL Mont-Godinne, Yvoir, Not set
Ministerio da Saude Instituto Nacional do Cancer, Rio De Janeiro, Not set
Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Not set
Instituto de Ensino e Pesquisa São Lucas, Sao Paulo, Not set
Jewish General Hospital, Montreal, Quebec
Peking University People s Hospital, Beijing, Not set
Peking University Third Hospital, Beijing, Not set
Peking University First Hospital, Beijing, Not set
West China Hospital Sichuan University, Chengdu, Not set
Fujian Medical University, Fuzhou, Not set
Sun Yat-sen University Cancer Hospital, Guangzhou, Not set
Zhejiang University First Hospital, Hangzhou, Not set
Ruijin Hospital, Shanghai, Not set
Tangdu hospital the Fourth Military Medical, Shanxi, Not set
The First Affliated Hospital of Soochow University, Suzhou, Not set
The Institute of Hematological disease, Tianjin, Not set
Wuhan Union Hospital, Wuhan, Not set
Fundacion Santa Fe, Bogota, Not set
Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Not set
Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Not set
Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Not set
Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set
Hopital Henri Mondor, Creteil, Not set
Hôpital E. Muller, Mulhouse, Not set
Hopital Necker Enfants Malades, Paris cedex 15, Not set
HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, Not set
Hopital Haut Leveque Service Maladie Du Sang, Pessac, Not set
CH LYON SUD - Hematology, Pierre Benite, Not set
CHU de Tours, Tours, Not set
Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Not set
Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Haus, Dresden, Not set
Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Not set
Justus-Liebig-Universitaet - Medizinische Klinik IV, Haematologie, Gießen, Not set
Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Not set
Universitätsklinikum des Saarlandes, Homburg/Saar, Not set
Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Not set
OnkoNet Marburg GmbH, Marburg, Not set
Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Not set
Laiko General Hospital - 1st department of Internal Medicine, Athens, Not set
G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set
Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/a, Not set
Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Not set
St James's Hospital, Dublin, Not set
Haemek Medical Center, Afula, Not set
Hillel Yaffe Medical Center - Oncology, Hadera, Not set
Rambam Health Care Campus, Haifa, Not set
Rabin Medical Center Beilinson Campus, Petah Tikva, Not set
Sheba Medical Center, Ramat-Gan, Not set
Tel Aviv Sourasky Medical Center, Tel Aviv, Not set
ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set
DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, Not set
A.O.Citta della Salute e della Scienza di Torino, Torino, Not set
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Not set
Hiroshima University Hospital, Hiroshima shi, Not set
Hokkaido University Hospital, Sapporo-shi, Not set
National Cancer Center, Goyang-Si, Not set
The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set
Oaxaca Site Management Organization S.C., Oaxaca, Not set
VU medisch centrum - Afd.Interne - INT, Amsterdam, Not set
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set
Uniwersyteckie Centrum Kliniczne, Gdansk, Not set
Pratia MCM Krakow, Krakow, Not set
Oddzial Hematologii, Opole, Not set
Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Not set
Katedra I Klinika Hematologii Nowotworow Krwi I Transplantacji Szpiku, Wroclaw, Not set
Instituto Portugues de Oncologia, Lisboa, Not set
Hospital De Santa Maria, Lisbon, Not set
Instituto Portugues de Oncologia, Porto, Not set
Auxilio Mutuo Cancer Center, San Juan, Not set
Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Not set
Chelyabinsk Regiona Onc. Center, Chelyabinsk, Not set
Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Not set
Cancer Research Center, Moscow N/a, Not set
S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set
Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Not set
Medical Scientific Radiology - Center, Obninsk, Not set
Perm Medical Sanitary Unit#1, Perm, Not set
Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set
Rostov Research Institute of Oncology, Rostov-Na-Donu, Not set
Ryazan Regional Clinical Hospital, Ryazan, Not set
Leningrad region clinical hospital, Saint, Not set
Samara Region Clinical Hospital, Samara, Not set
Federal Center of Heart, Blood and Endocrinology, Sankt-Peterburg, Not set
Oncological dispensary #2, Sochi, Not set
City Clinical Oncology Dispensary, St. Petersburg, Not set
Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Not set
Oncology Dispensary of Komi Republic, Syktyvkar, Not set
Hospital Vall d'Hebron, Barcelona N/a, Not set
Inst. Cat. Doncologia-H Duran I Reynals, L'hospitalet De Llobregat, Not set
Hosp. Univ. de La Princesa, Madrid, Not set
Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set
Hosp. Univ. Infanta Leonor, Madrid, Not set
Fundacion Jimenez Diaz, Madrid, Not set
Clinica Universitaria de Navarra, Pamplona N/a, Not set
Hospital Clinico Universitario Salamanca, Salamanca, Not set
Sahlgrenska University hospital, Hematology Dept, Göteborg, Not set
Skanes universitetssjukhus, Lund, Not set
Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Not set
Changhua Cristian Hospital, Changhua County, Not set
Ankara University, Ankara, Not set
American Hospital, Istanbul, Not set
Istanbul University, Istanbul, Not set
Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set
Erciyes University, Kayseri, Not set
Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set
Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set
SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Not set
Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Not set
State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Not set
Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Not set
Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set
University Hospitals Birmingham NHS Trust,, Birmingham, Not set
Royal Bournemouth Hospital, Bournemouth, Not set
Colchester Hospital University NHS, Colchester, Not set
Beatson West Of Scotland Cancer Centre, Glasgow, Not set
St James's Institute of Oncology, Leeds, Not set
Leicester Royal Infirmary - Haematology, Leicester, Not set
St Bartholomew's Hospital - Dept of Haematology, London, Not set
University College London Hospitals NHSFT, London, Not set
Kings College Hospital, London, Not set
Christie Hospital, Manchester, Not set
Nottingham University Hospitals NHS Trust, Nottingham, Not set
Derriford Hospital, Plymouth, Not set
Royal Hallamshire Hospital, Sheffield, Not set
Southampton General Hospital, Southampton, Not set
Royal Marsden Hospital (Sutton), Sutton, Not set
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Recruiting
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona +198 locations
The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona
Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos, California
Cedars-Sinai Medical Center ( Site 0115), Los Angeles, California
Bioresearch Partner ( Site 0157), Hialeah, Florida
Cancer Care Specialists of Illinois ( Site 0152), O'Fallon, Illinois
Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne, Indiana
Cotton O'Neil Cancer Center ( Site 0108), Topeka, Kansas
Corewell Health ( Site 0130), Grand Rapids, Michigan
Truman Medical Center ( Site 0122), Kansas City, Missouri
OptumCare Cancer Care ( Site 0121), Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada ( Site 0113), Las Vegas, Nevada
New York Oncology Hematology, P.C. ( Site 0129), Albany, New York
The University of Tennessee Medical Center ( Site 0142), Knoxville, Tennessee
University of Virginia Cancer Center ( Site 0138), Charlottesville, Virginia
Virginia Cancer Institute ( Site 0148), Richmond, Virginia
Blue Ridge Cancer Care ( Site 0132), Roanoke, Virginia
SSM Health Dean Medical Group ( Site 0140), Madison, Wisconsin
Clinica Adventista Belgrano ( Site 0309), Caba., Buenos Aires
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0306), Mar del Plata, Buenos Aires
Hospital Universitario Austral ( Site 0307), Pilar, Buenos Aires
Hospital Aleman ( Site 0301), Buenos Aites, Caba
Fundacion Estudios Clinicos ( Site 0311), Rosario., Santa Fe
C.I.C.E. 9 de Julio ( Site 0305), San Miguel de Tucuman, Tucuman
Hospital Italiano de Buenos Aires ( Site 0304), Caba, Not set
Clinica EL Castaño ( Site 0312), San Juan, Not set
Townsville University Hospital ( Site 3006), Douglas, Queensland
Grampians Health ( Site 3003), Ballarat, Victoria
Royal Perth Hospital-Haematology ( Site 3004), Perth, Western Australia
AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 1102), Mechelen, Antwerpen
ASBL CHU Helora - Hôpital de Mons - Site Kennedy ( Site 1103), Mons, Hainaut
CEONC ( Site 0412), Cascavel, Parana
Hospital Erasto Gaertner ( Site 0401), Curitiba, Parana
Liga Norte Riograndense Contra o Cancer ( Site 0407), Natal, Rio Grande Do Norte
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0403), Florianópolis, Santa Catarina
Hope ( Site 0413), Ribeirao Preto, Sao Paulo
Clinica Advanze ( Site 0411), Sao Carlos, Sao Paulo
F. F. R. M. São Jose do Rio Preto ( Site 0404), Sjrp, Sao Paulo
Hospital Paulistano ( Site 0406), Sao Paulo, Not set
Lakeridge Health - The R.S. McLaughlin Durham Regional Cancer Centre (MDRCC) ( Site 0206), Oshawa, Ontario
Biocenter ( Site 0510), Concepcion., Biobio
IC La Serena Research ( Site 0504), La Serena, Coquimbo
Oncocentro Valdivia ( Site 0506), Valdivia, Los Rios
Centro de Estudios Clínicos SAGA ( Site 0508), Santiago., Region M. De Santiago
Bradfordhill ( Site 0502), Santiago., Region M. De Santiago
FALP ( Site 0501), Santiago, Region M. De Santiago
Clinica Inmunocel ( Site 0503), Santiago, Region M. De Santiago
Clínica RedSalud Vitacura ( Site 0512), Santiago, Region M. De Santiago
Centro de Investigaciones ( Site 0511), Vina del mar, Valparaiso
Anhui Provincial Cancer Hospital ( Site 3124), Hefei, Anhui
Peking University Third Hospital ( Site 3102), Beijing, Beijing
Beijing Cancer Hospital ( Site 3101), Beijing, Beijing
Chongqing Cancer Hospital ( Site 3113), Chongqing, Chongqing
Fujian Provincial Cancer Hospital. ( Site 3119), Fuzhou, Fujian
The First Affiliated Hospital of Xiamen University ( Site 3120), Xiamen, Fujian
Sun Yat-sen University Cancer Center ( Site 3121), Guangzhou, Guangdong
Zhujiang Hospital of Southern Medical University ( Site 3122), Guangzhou, Guangdong
Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123), Nanning, Guangxi
The Affiliated Hospital of Guizhou Medical University ( Site 3112), Guiyang, Guizhou
Hubei Cancer Hospital ( Site 3125), Wuhan, Hubei
Affiliated Hospital of Nantong University ( Site 3117), Nantong, Jiangsu
Jiangxi Cancer Hospital ( Site 3118), Nanchang, Jiangxi
The First Hospital Of Jilin University ( Site 3103), Changchun, Jilin
Shandong Cancer Hospital ( Site 3108), Jinan, Shandong
LinYi Cancer Hospital ( Site 3104), Linyi, Shandong
Fudan University Shanghai Cancer Center ( Site 3115), Shanghai, Shanghai
Shanxi Cancer Hospital ( Site 3106), Taiyuan, Shanxi
1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 3107), XI An, Shanxi
Sichuan Cancer Hospital. ( Site 3111), Chengdu, Sichuan
West China Hospital, Sichuan University ( Site 3110), Chengdu, Sichuan
Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105), Tianjin, Tianjin
Yunnan Province Cancer Hospital ( Site 3109), Kunming, Yunnan
The First Affiliated Hospital, Zhejiang Medical University ( Site 3116), Hangzhou, Zhejiang
Hospital Pablo Tobon Uribe ( Site 0604), Medellin, Antioquia
IMAT S.A.S ( Site 0603), Montería, Cordoba
Hospital Universitario San Ignacio ( Site 0607), Bogota., Distrito Capital De Bogota
Oncologos del Occidente ( Site 0601), Pereira., Risaralda
Fundación Valle del Lili ( Site 0602), Cali, Valle Del Cauca
Regionshospitalet Gødstrup ( Site 1301), Herning, Midtjylland
Aalborg University Hospital ( Site 1302), Aalborg, Nordjylland
Centre Antoine-Lacassagne ( Site 1514), Nice, Alpes-Maritimes
CHU Dijon Bourgogne ( Site 1516), Dijon, Cote-d Or
Institut Curie - site Saint-Cloud ( Site 1501), Saint-Cloud, Hauts-de-Seine
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1512), Limoges, Limousin
Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy ( Site 1515), Metz, Moselle
Centre Hospitalier de Dunkerque ( Site 1513), Dunkerque, Nord
Centre Hospitalier Universitaire Estaing ( Site 1508), Clermont-Ferrand, Puy-de-Dome
Centre Hospitalier de la Cote Basque ( Site 1509), Bayonne, Pyrenees-Atlantiques
HIA Sainte Anne ( Site 1506), Toulon, Var
Centre Hospitalier d'Avignon ( Site 1505), Avignon, Vaucluse
CHD Vendee ( Site 1502), La Roche-sur-Yon, Vendee
Evangelismos General Hospital of Athens ( Site 1602), Athens, Attiki
General Hospital of Athens "Laiko"-Hematology Department ( Site 1603), Athens, Attiki
Attikon University General Hospital of Athens ( Site 1604), Athens, Attiki
University General Hospital of Alexandroupoli ( Site 1601), Alexandroupolis, Evros
CELAN,S.A ( Site 0702), Guatemala., Not set
MEDI-K ( Site 0701), Guatemala, Not set
Cen Integral Onco Gastro y Hemato Onco Guatemala S.A. ( Site 0703), Guatemala, Not set
Princess Margaret Hospital ( Site 3202), Hong Kong, Not set
Queen Mary Hospital ( Site 3201), Hong Kong, Not set
Carmel Hospital ( Site 1903), Haifa, Not set
Hadassah Medical Center ( Site 1901), Jerusalem, Not set
Sourasky Medical Center ( Site 1904), Tel Aviv, Not set
Poria Medical Center ( Site 1902), Tiberias, Not set
Fondazione IRCCS San Gerardo dei Tintori ( Site 2008), Monza, Lombardia
IRCCS Crob ( Site 2002), Rionero in Vulture, Potenza
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia ( Site 2010), Candiolo, Torino
AOU delle Marche Ospedali Riuniti di Ancona ( Site 2011), Ancona, Not set
Azienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 2001), Brescia, Not set
IRCCS Ospedale San Raffaele ( Site 2012), Milano, Not set
IEO Istituto Europeo di Oncologia ( Site 2009), Milano, Not set
Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 2004), Novara, Not set
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO ( Site 2005), Palermo, Not set
Ospedale Santa Maria delle Croci ( Site 2006), Ravenna, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 2003), Roma, Not set
Nagoya University Hospital ( Site 3309), Nagoya, Aichi
National Hospital Organization Shikoku Cancer Center ( Site 3321), Matsuyama, Ehime
Kobe City Medical Center General Hospital ( Site 3318), Kobe, Hyogo
Kanazawa University Hospital ( Site 3308), Kanazawa, Ishikawa
Tokai University Hospital ( Site 3302), Isehara, Kanagawa
Tohoku University Hospital ( Site 3301), Sendai, Miyagi
Kindai University Hospital ( Site 3310), Osakasayama, Osaka
Saitama Medical University Hospital ( Site 3305), Iruma-gun, Saitama
Juntendo University Hospital ( Site 3307), Bunkyo, Tokyo
University of Yamanashi Hospital ( Site 3320), Chuo, Yamanashi
Chiba Cancer Center ( Site 3314), Chiba, Not set
Kyushu University Hospital ( Site 3313), Fukuoka, Not set
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 3322), Hiroshima, Not set
University Hospital,Kyoto Prefectural University of Medicine ( Site 3315), Kyoto, Not set
University of Miyazaki Hospital ( Site 3319), Miyazaki, Not set
Okayama University Hospital ( Site 3311), Okayama, Not set
Osaka Metropolitan University Hospital ( Site 3317), Osaka, Not set
Yamagata University Hospital ( Site 3312), Yamagata, Not set
National Cancer Center- Center for Hemotologic malignancy ( Site 3806), Goyang-si, Kyonggi-do
Pusan National University Hospital ( Site 3804), Busan, Pusan-Kwangyokshi
Chungnam National University Hospital ( Site 3801), Daejeon, Taejon-Kwangyokshi
Severance Hospital, Yonsei University Health System ( Site 3802), Seoul, Not set
Asan Medical Center ( Site 3803), Seoul, Not set
Samsung Medical Center ( Site 3807), Seoul, Not set
St.Mary's H., Youido ( Site 3805), Seoul, Not set
Queen Elizabeth Hospital ( Site 3405), Kota Kinabalu, Sabah
Sarawak General Hospital ( Site 3402), Kuching, Sarawak
Hospital Miri ( Site 3403), Miri, Sarawak
Sunway Medical Centre ( Site 3406), Petaling Jaya, Selangor
Hospital Ampang ( Site 3404), Selangor Darul Ehsan, Selangor
Centro de Infusion Superare ( Site 0804), Ciudad de Mexico, Distrito Federal
Health Pharma Professional Research S.A. de C.V. ( Site 0801), Mexico City, Distrito Federal
Grupo Ollin Care ( Site 0806), Pachuca, Hidalgo
Centro de Investigacion Clinica Chapultepec ( Site 0803), Morelia, Michoacan
Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"" ( Site 0802), Monterrey, Nuevo Leon
Centro de Investigacion Clinica de Oaxaca ( Site 0805), Oaxaca, Not set
Meander Medisch Centrum ( Site 2101), Amersfoort, Utrecht
Albert Schweitzer Ziekenhuis ( Site 2103), Dordrecht, Zuid-Holland
Clínicas AUNA Sede Chiclayo ( Site 0904), Chiclayo, Lambayeque
Clínica San Felipe ( Site 0906), Lima, Not set
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2201), Warszawa, Mazowieckie
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 2210), Słupsk, Pomorskie
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2208), Gliwice, Slaskie
Pratia Onkologia Katowice ( Site 2204), Katowice, Slaskie
Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2205), Olsztyn, Warminsko-mazurskie
Unidade Local de Saude de Braga - Hospital de Braga ( Site 2306), Braga, Not set
Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2302), Porto, Not set
BRCR Global - Mayaguez ( Site 1003), Mayaguez, Not set
Auxilio Mutuo Cancer Center ( Site 1001), San Juan, Not set
Institutul Oncologic Cluj ( Site 2404), Cluj-Napoca, Cluj
Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 2402), Brasov, Not set
Spital Judetean Sibiu ( Site 2405), Sibiu, Not set
National University Hospital ( Site 3702), Singapore, Central Singapore
National Cancer Centre Singapore ( Site 3701), Singapore, Central Singapore
Haemalife ( Site 2501), Cape Town, Western Cape
Hospital Universitario Virgen Macarena ( Site 2608), Sevilla, Andalucia
ICO L Hospitalet ( Site 2601), Hospitalet de Llobregat, Barcelona
H. Insular de Gran Canaria ( Site 2606), Las Palmas de Gran Canaria, Las Palmas
Hospital General Universitario Dr. Balmis ( Site 2604), Alicante, Valenciana, Comunitat
Hospital del Mar ( Site 2610), Barcelona, Not set
Hospital Universitario La Paz ( Site 2611), Madrid, Not set
Hospital Virgen de la Victoria ( Site 2609), Malaga, Not set
Hospital Universitario Miguel Servet ( Site 2607), Zaragoza, Not set
Kantonspital Baden ( Site 2703), Baden, Aargau
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 2702), St. Gallen, Sankt Gallen
Ospedale Regionale Bellinzona e Valli ( Site 2701), Bellinzona, Ticino
Chang Gung Memorial Hospital - Linkou Branch ( Site 3903), Taoyuan City, Taoyuan
Chang Gung Memorial Hospital at Kaohsiung ( Site 3905), Kaohsiung, Not set
National Cheng Kung University Hospital ( Site 3902), Tainan, Not set
National Taiwan University Hospital ( Site 3901), Taipei, Not set
Mackay Memorial Hospital ( Site 3908), Taipei, Not set
Tri-Service General Hospital ( Site 3906), Taipei, Not set
Maharaj Nakorn Chiang Mai Hospital ( Site 4002), Muang, Chiang Mai
Faculty of Medicine Siriraj Hospital ( Site 4001), Bangkoknoi, Krung Thep Maha Nakhon
Chulalongkorn University ( Site 4003), Pathumwan, Krung Thep Maha Nakhon
Hacettepe Universite Hastaneleri ( Site 2810), Ankara, Not set
Ankara University Faculty of Medicine ( Site 2801), Ankara, Not set
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2904), Cherkasy, Cherkaska Oblast
Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2906), Ivano-Frankivsk, Ivano-Frankivska Oblast
Khmelnytskyi Regional Hospital ( Site 2907), Khmelnytskiy, Khmelnytska Oblast
Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903), Lviv, Lvivska Oblast
SNPE National Cancer Institute ( Site 2902), Kyiv, Not set
Universal Clinic Oberig ( Site 2908), Kyiv, Not set
SI National Research Center of Radiation Medicine, Hematology, Oncology ( Site 2901), Kyiv, Not set
Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2905), Kyiv, Not set
Conditions: Diffuse Large B-Cell Lymphoma
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), or R/R CLL. Adverse events will be assessed.
ABBV-319 is an investigational drug being developed for the treatment of R/R DLBCL, R/R FL, or R/R CLL. This study will include a dose escalation phase to determine the doses of ABBV-319 that will be used in the next phase and a dose expansion phase to determine the change in disease activity in participants with R/R DLBCL, R/R FL, and R/R CLL. Approximately 154 adult participants with R/R B cell lymphomas including R/R DLBCL, R/R FL, and R/R CLL will be enrolled in the study in sites world wide.
In the Dose Escalation phase of the study participants will receive escalating intravenously infused doses of ABBV-319 in 21-day cycles, until the Phase 2 dose is determined. In the dose expansion phase of the study participants receive intravenously infused ABBV-319 in 21-day cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +17 locations
University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona
Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232, Miami, Florida
Allina Health System /ID# 251782, Minneapolis, Minnesota
University of Nebraska Medical Center /ID# 246715, Omaha, Nebraska
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246, New York, New York
Novant Health Presbyterian Medical Center /ID# 246719, Charlotte, North Carolina
Baylor Sammons Cancer Center /ID# 247715, Dallas, Texas
University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234, San Antonio, Texas
Concord Repatriation General Hospital /ID# 249240, Concord, New South Wales
St Vincent's Hospital Melbourne /ID# 247624, Fitzroy Melbourne, Victoria
One Clinical Research Pty Ltd /ID# 248392, Nedlands, Western Australia
Cross Cancer Institute /ID# 246717, Edmonton, Alberta
University Health Network_Princess Margaret Cancer Centre /ID# 243936, Toronto, Ontario
The Chaim Sheba Medical Center /ID# 254884, Ramat Gan, Tel-Aviv
Hadassah Medical Center-Hebrew University /ID# 254885, Jerusalem, Not set
Seoul National University Hospital /ID# 263945, Seoul, Seoul Teugbyeolsi
Asan Medical Center /ID# 263220, Seoul, Seoul Teugbyeolsi
Samsung Medical Center /ID# 263294, Seoul, Seoul Teugbyeolsi
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +33 locations
Alaska Oncology & Hematology, LLC, Anchorage, Alaska
Providence Medical Foundation, Fullerton, California
Valkyrie Clinical Trials, Los Angeles, California
Zuckerberg San Francisco General Hospital, San Francisco, California
Rocky Mountain Cancer Centers, LLP, Aurora, Colorado
Mount Sinai Comprehensive Cancer Center, Miami, Florida
St Luke?s Cancer Institute, Boise, Idaho
Cancer Care Specialists of Central Illinois, Swansea, Illinois
University of Kentucky - Markey Cancer Center, Lexington, Kentucky
Boston Medical Center, Boston, Massachusetts
Nebraska Cancer Specialists, Omaha, Nebraska
New York Oncology Hematology, P.C., Albany, New York
Oncology Associates of Oregon, P.C, Eugene, Oregon
Texas Oncology - Gulf Coast, The Woodlands, Texas
Texas Oncology- Northeast Texas, Tyler, Texas
Virginia Cancer Specialists, PC, Gainesville, Virginia
Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia
Northwest Medical Specialties, Tacoma, Washington
Arthur J.E. Child Comprehensive Cancer Center, Calgary, Alberta
CancerCare Manitoba (CCMB), Winnipeg, Manitoba
CHU de Grenoble, La Tronche, Not set
Chu de Montpellier-St Eloi, Montpellier, Not set
CHU de Bordeaux, Pessac, Not set
CHU DE RENNES - CHU Pontchaillou, Rennes, Not set
Chu De Tours, Tours, Not set
Otto von Guericke Uni Magdeburg Uniklinik, Magdeburg, Not set
Istituto Nazionale Tumori Irccs Fondazione g. Pascale, Napoli, Campania
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori", Meldola, Emilia-Romagna
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili, Brescia, Lombardia
Irccs Istituto Europeo Di Oncologia (IEO), Milano, Lombardia
Istituto Clinico Humanitas, Rozzano, Lombardia
Seoul National University Bundang Hospital, Seongnam-si, Not set
Seoul National University Hospital, Seoul, Not set
Asan Medical Center, Seoul, Not set
Conditions: Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
Epcoritamab is an investigational drug being... Read More
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBCL will be enrolled in approximately 165 sites across the world.
Participants in arm A will receive subcutaneous (SC) injections of epcoritamab plus oral lenalidomide capsules (E-Len) for up to 12 cycles (each cycle is 28 days). Participants in arm B will receive intravenously (IV) infused R-GemOx for up to 4 cycles (each cycle is 28 days). Participants in arm C will receive SC injections of epcoritamab for up to 12 cycles (each cycle is 28 days).
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: City of Hope National Medical Center /ID# 273338, Duarte, California +152 locations
City of Hope National Medical Center /ID# 273338, Duarte, California
Valkyrie Clinical Trials /ID# 269935, Los Angeles, California
Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823, Golden, Colorado
City Of Hope Cancer Center - Atlanta /ID# 273092, Newnan, Georgia
City of Hope, Chicago /ID# 274430, Zion, Illinois
Northwest Cancer Center - Dyer Clinic /ID# 269787, Dyer, Indiana
Cancer Center of Kansas - Wichita /ID# 270117, Wichita, Kansas
University of Kentucky Chandler Medical Center /ID# 242087, Lexington, Kentucky
University of Maryland, Baltimore /ID# 242216, Baltimore, Maryland
Henry Ford Hospital /ID# 266446, Detroit, Michigan
Gulfport Memorial Hospital /ID# 268104, Gulfport, Mississippi
New York Medical College /ID# 265799, Valhalla, New York
East Carolina University - Brody School of Medicine /ID# 242227, Greenville, North Carolina
Thompson Cancer Survival Ctr /ID# 242149, Knoxville, Tennessee
Community Cancer Trials Of Utah /ID# 271715, Ogden, Utah
Utah Cancer Specialists - Salt Lake City /ID# 268603, Salt Lake City, Utah
Veterans Affairs Medical Center - Salt Lake City /ID# 265329, Salt Lake City, Utah
Canberra Hospital /ID# 265312, Garran, Australian Capital Territory
Royal Prince Alfred Hospital /ID# 263242, Sydney, New South Wales
Wollongong Hospital /ID# 244646, Wollongong, New South Wales
Toowoomba Hospital /ID# 263243, Toowoomba, Queensland
Monash Health - Monash Medical Centre /ID# 262783, Clayton, Victoria
Royal Perth Hospital /ID# 243790, Perth, Western Australia
Universitair Ziekenhuis Brussel /ID# 242574, Jette, Bruxelles-Capitale
Centre Hospitalier Epicura - site d'Hornu /ID# 265148, Boussu, Hainaut
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 242565, Yvoir, Namur
Universitair Ziekenhuis Leuven /ID# 246671, Leuven, Vlaams-Brabant
AZ-Delta /ID# 264740, Roeselare, West-Vlaanderen
UMHAT Sveti Georgi /ID# 242905, Plovdiv, Not set
UMHAT Sveti Ivan Rilski /ID# 242389, Sofia, Not set
SHAT Hematologic Diseases /ID# 242708, Sofia, Not set
UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 262761, Varna, Not set
CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 262751, Montreal, Quebec
Peking University Third Hospital /ID# 242941, Beijing, Beijing
Fujian Province Cancer Hospital /ID# 265075, Fuzhou, Fujian
The First Affiliated Hospital of Xiamen /ID# 264305, Xiamen, Fujian
Sun Yat-Sen University Cancer Center /ID# 242712, Guangzhou, Guangdong
Guangdong Provincial People's Hospital /ID# 242942, Guangzhou, Guangdong
The Second Hospital of Hebei Medical University /ID# 242944, Shijiazhuang, Hebei
Harbin Medical University Cancer Hospital /Id# 242961, Harbin, Heilongjiang
Henan Cancer Hospital /ID# 242700, Zhengzhou, Henan
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 242702, Wuhan, Hubei
Hubei Cancer Hospital /ID# 242963, Wuhan, Hubei
The First Affiliated Hospital of Soochow University /ID# 242939, Suzhou, Jiangsu
The First Affiliated Hospital of Nanchang University /ID# 242703, Nanchang, Jiangxi
Jiangxi Provincial Cancer Hospital /ID# 242968, Nanchang, Jiangxi
The First Hospital of Jilin University /ID# 242940, Changchun, Jilin
The First Hospital of China Medical University /ID# 242701, Shenyang, Liaoning
Shandong Cancer Hospital /ID# 264036, Jinan, Shandong
Shanghai Tongji Hospital /ID# 263952, Shanghai, Shanghai
Tianjin Cancer Hospital /ID# 243940, Tianjin, Tianjin
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 243139, Tianjin, Tianjin
The Affiliated Cancer Hospital of Xinjiang Medical University /ID# 242966, Urumqi, Xinjiang
Yunnan Province Cancer Hospital /ID# 264057, Kunming, Yunnan
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 242960, Hangzhou, Zhejiang
The second affiliated hospital of Zhejiang University school of medicine /ID# 243137, Hangzhou, Zhejiang
Zhejiang Cancer hospital /ID# 242711, Hangzhou, Zhejiang
The First Affiliated Hospital of Wenzhou Medical University /ID# 263951, Wenzhou, Zhejiang
Klinicka bolnica Merkur /ID# 262619, Zagreb, Grad Zagreb
Klinicki bolnicki centar Sestre milosrdnice /ID# 262620, Zagreb, Grad Zagreb
Klinicki bolnicki centar Zagreb /ID# 262617, Zagreb, Grad Zagreb
Klinicki bolnicki centar Osijek /ID# 262621, Osijek, Osjecko-baranjska Zupanija
Klinički Bolnički Centar Rijeka /ID# 266004, Rijeka, Primorsko-goranska Zupanija
Klinicki Bolnicki Centar (KBC) Split /ID# 262618, Split, Splitsko-dalmatinska Zupanija
Fakultní nemocnice Hradec Králové - Sokolská /ID# 264071, Hradec Králové, Hradec Kralove
Institut de cancérologie Strasbourg Europe (ICANS) /ID# 264068, Strasbourg, Bas-Rhin
CHU de CAEN - Hopital de la Cote de Nacre /ID# 243075, Caen, Calvados
CHRU Tours - Hopital Bretonneau /ID# 244580, Tours CEDEX 9, Indre-et-Loire
Centre Hospitalier D'Avignon /ID# 243072, Avignon, Provence-Alpes-Cote-d Azur
Centre Hospitalier de la Cote Basque /ID# 243065, Bayonne, Pyrenees-Atlantiques
CHU Poitiers - La miletrie /ID# 243074, Poitiers, Vienne
Hopital Saint Vincent de Paul /ID# 243070, Lille Cedex, Not set
General Hospital of Athens Laiko /ID# 262809, Athens, Attiki
University General Hospital Attikon /ID# 242041, Athens, Attiki
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 242039, Athens, Not set
General University Hospital of Thessaloniki AXEPA /ID# 242038, Thessaloniki, Not set
Theageneio Anticancer Hospital /ID# 242036, Thessaloniki, Not set
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 262924, Pecs, Baranya
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 262901, Gyor, Gyor-Moson-Sopron
Debreceni Egyetem-Klinikai Kozpont /ID# 242451, Debrecen, Hajdu-Bihar
Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 242468, Nyiregyhaza, Szabolcs-Szatmar-Bereg
Semmelweis Egyetem /ID# 242455, Budapest, Not set
Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 262923, Budapest, Not set
Orszagos Onkologiai Intezet /ID# 242457, Budapest, Not set
Fujita Health University Hospital /ID# 265968, Toyoake, Aichi
National Hospital Organization Shikoku Cancer Center /ID# 265977, Matsuyama, Ehime
Kyushu University Hospital /ID# 267624, Fukuoka-shi, Fukuoka
Fukushima Medical University Hospital /ID# 264667, Fukushima-shi, Fukushima
Sapporo Medical University Hospital /ID# 264928, Sapporo, Hokkaido
Kagoshima University Hospital /ID# 248259, Kagoshima-shi, Kagoshima
Tokai University Hospital /ID# 265433, Isehara, Kanagawa
Kansai Medical University Hirakata Hospital /ID# 266018, Hirakata-shi, Osaka
Kindai University Hospital /ID# 265474, Osaka sayama-shi, Osaka
Saitama Cancer Center /ID# 265277, Kitaadachi-gun, Saitama
University of Yamanashi Hospital /ID# 264671, Chuo-shi, Yamanashi
Inje University - Busan Paik Hospital /ID# 262842, Busan, Busan Gwang Yeogsi
Dong-A University Medical Center /ID# 262841, Busan, Busan Gwang Yeogsi
Seoul National University Bundang Hospital /ID# 242405, Seongnam-si, Gyeonggido
Keimyung University Dongsan Hospital /ID# 262840, Daegu, Gyeongsangbugdo
Jeonbuk National University Hospital /ID# 242958, Jeonju, Jeonrabugdo
Chonnam National University Hwasun Hospital /ID# 262843, Hwasun-gun, Jeonranamdo
Seoul National University Hospital /ID# 242407, Seoul, Seoul Teugbyeolsi
Asan Medical Center /ID# 242409, Seoul, Seoul Teugbyeolsi
Samsung Medical Center /ID# 242408, Seoul, Seoul Teugbyeolsi
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242406, Seoul, Seoul Teugbyeolsi
Ulsan University Hospital /ID# 242956, Ulsan, Ulsan Gwang Yeogsi
Centro De Investigación Clinica Chapultepec /ID# 243959, Mexico City, Ciudad De Mexico
Centro de Quimioterapia E Investigacion Sas de Cv /Id# 263293, Jalisco, Not set
Medisch Centrum Leeuwarden /ID# 245501, Leeuwarden, Friesland
Jeroen Bosch Ziekenhuis, locatie 's-Hertogenbosch /ID# 265204, 's-Hertogenbosch, Noord-Brabant
OLVG - Locatie Oost /ID# 263355, Amsterdam, Noord-Holland
St. Antonius Ziekenhuis /ID# 245197, Nieuwegein, Utrecht
Albert Schweitzer Ziekenhuis, locatie Dordwijk /ID# 263361, Dordrecht, Zuid-Holland
North Shore Hospital /ID# 266060, Auckland, Not set
Wellington Hospital /ID# 265966, Wellington, Not set
Pratia MCM Krakow /ID# 262882, Krakow, Malopolskie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 263314, Warsaw, Mazowieckie
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 242436, Kielce, Swietokrzyskie
Aidport sp z o.o. /ID# 262766, Poznan, Wielkopolskie
Hospital da Luz /ID# 262965, Lisbon, Lisboa
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE /ID# 262961, Porto, Not set
Unidade Local de Saude Sao Joao, EPE /ID# 262962, Porto, Not set
Fundeni Clinical Institute /ID# 266734, Bucharest, Bucuresti
Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca /ID# 243753, Cluj-Napoca, Cluj
Institutul Regional de Oncologie /ID# 244367, Jassi, Iasi
Spitalul Clinic Coltea /ID# 243694, Bucharest, Not set
Clinical Hospital Center Zvezdara /ID# 263059, Belgrade, Beograd
Institute for Oncology and Radiology of Serbia /ID# 263055, Belgrade, Beograd
University Clinical Center Serbia /ID# 263057, Belgrade, Beograd
Clinical Hospital Center - Bežanijska Kosa /ID# 263053, Belgrade, Beograd
University Clinical Center Nis /ID# 263701, Niš, Nisavski Okrug
Institute for Oncology of Vojvodina /ID# 263052, Sremska Kamenica, Vojvodina
University Clinical Center Vojvodina /ID# 264138, Novi Sad, Not set
National Cancer Centre Singapore /ID# 267015, Singapore, Central Singapore
National University Hospital /ID# 264016, Singapore, Not set
Tan Tock Seng Hospital /ID# 266061, Singapore, Not set
Wits Clinical Research /ID# 264656, Johannesburg, Gauteng
Alberts Cellular Therapy /ID# 262720, Pretoria, Gauteng
Constantiaberg Haematology /ID# 273041, Cape Town, Western Cape
Haemalife Inc. /ID# 262719, Kuilsrivier, Western Cape
National Taiwan University Hospital /ID# 243300, Taipei City, Taipei
China Medical University Hospital /ID# 242931, Taichung, Not set
Taichung Veterans General Hospital /ID# 242937, Taichung, Not set
National Cheng Kung University Hospital /ID# 243301, Tainan, Not set
Ankara Universitesi Fakultesi /ID# 242410, Ankara, Not set
Adnan Menderes University /ID# 242418, Aydin, Not set
Trakya University Medical Facu /ID# 242419, Edirne, Istanbul, Not set
Ege University Medical Faculty /ID# 242417, Izmir, Not set
Ondokuz mayis University Facul /ID# 242412, Samsun, Not set
Karadeniz Technical University Farabi Hospital /ID# 264694, Trabzon, Not set
Istanbul Florence Nightingale Hospital /ID# 271544, Şişli, Not set
Nottingham City Hospital /ID# 265129, Nottingham, Nottinghamshire
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 242923, Newcastle upon Tyne, Not set
Conditions: Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Recruiting
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with bendamustine rituximab (BR) is superior to BR with respect to PFS per Lugano response criteria by BICR.
With protocol amendment 4 (effective: 04-April-2024), enrollment in Cohort B (study arms Bendamustine Rituximab \[BR\] and ZV + BR) is discontinued. No efficacy outcome analysis and hypothesis testing will be conducted for Cohort B. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +108 locations
Bass Medical Group ( Site 0166), Walnut Creek, California
Innovative Clinical Research Institute ( Site 0122), Whittier, California
Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida
Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky
University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky
Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana
University of Maryland ( Site 0123), Baltimore, Maryland
Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts
University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts
St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana
Atlantic Health System ( Site 0116), Morristown, New Jersey
New York Medical College ( Site 0113), Valhalla, New York
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee
Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires
Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata., Buenos Aires
Hospital Aleman ( Site 2200), Buenos Aites, Caba
Instituto Alexander Fleming ( Site 2201), Caba, Not set
Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set
Townsville University Hospital ( Site 1800), Douglas, Queensland
Grampians Health ( Site 1802), Ballarat, Victoria
Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia
Hospital Erasto Gaertner ( Site 2302), Curitiba, Parana
Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande Do Norte
Hospital Paulistano ( Site 2300), Sao Paulo, Not set
Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306), Sao Paulo, Not set
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario
Biocenter ( Site 2401), Concepcion., Biobio
IC La Serena Research ( Site 2405), La Serena, Coquimbo
Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios
FALP-UIDO ( Site 2400), Santiago., Region M. De Santiago
Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago
Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago
Bradfordhill ( Site 2403), Santiago, Region M. De Santiago
Beijing Cancer hospital ( Site 3000), Beijing, Beijing
Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing
Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing
Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong
Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong
The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan
Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei
The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi
Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi
The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin
Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai
West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan
Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan
Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang
The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang
Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia
Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogota, Distrito Capital De Bogota
Oncologos del Occidente ( Site 0800), Pereira., Risaralda
Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca
Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose
CIMCA ( Site 2501), San Jose, Not set
centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone
Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set
University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki
Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki
Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki
MEDI-K ( Site 2602), Guatemala, Not set
Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set
CELAN,S.A ( Site 2603), Guatemala, Not set
Queen Mary Hospital ( Site 3100), Hong Kong, Not set
Princess Margaret Hospital ( Site 3101), Hong Kong, Not set
Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set
Carmel Hospital ( Site 1103), Haifa, Not set
Hadassah Medical Center ( Site 1100), Jerusalem, Not set
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano
IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set
Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set
Samsung Medical Center ( Site 0300), Seoul, Not set
Health Pharma Professional Research S.A. de C.V: ( Site 2700), Ciudad de Mexico, Distrito Federal
Medivest Centro de Investigación Integral ( Site 2704), Chihuahua, Not set
Centro de Infusion Superare ( Site 2701), Mexico City, Not set
Aotearoa Clinical Trials ( Site 0501), Auckland, Not set
Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque
Clínica San Felipe ( Site 2805), Lima, Not set
Hospital Nacional Edgardo Rebagliati Martins ( Site 2802), Lima, Not set
Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Walbrzych, Dolnoslaskie
Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Dolnoslaskie
Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie
Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warszawa, Mazowieckie
Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie
Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie
Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon
Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon
Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara
Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir
Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set
Mega Medipol-Hematology ( Site 1909), Istanbul, Not set
Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set
Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast
Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivska Oblast
Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast
State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set
National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Not set
Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003), Kyiv, Not set
Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City
The Royal Cornwall Hospital ( Site 2103), Truro, England
University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of
Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Recruiting
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma. Read Less
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
07/18/2025
Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +56 locations
Children's Hospital Los Angeles ( Site 1006), Los Angeles, California
Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado
Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut
Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida
University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa
Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts
Corewell Health ( Site 1001), Grand Rapids, Michigan
Children's Mercy Hospital ( Site 1024), Kansas City, Missouri
Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey
New York Medical College ( Site 1023), Valhalla, New York
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota
Oregon Health and Science University ( Site 1004), Portland, Oregon
Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania
Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota
University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas
Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah
Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales
Queensland Children's Hospital-Oncology & Haematology ( Site 1996), Brisbane, Queensland
UZ Gent ( Site 1428), Gent, Oost-Vlaanderen
Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana
Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo
Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267), São José do Rio Preto, Sao Paulo
McGill University Health Centre-Pediatric HematologyOncology ( Site 1223), Montréal, Quebec
Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso
Hospital Pablo Tobon Uribe ( Site 1923), Medellin, Antioquia
Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla, Atlantico
IMAT S.A.S ( Site 1921), Monteria, Cordoba
Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467), Copenhagen, Hovedstaden
CHU de Bordeaux. Hopital Pellegrin ( Site 1105), Bordeaux, Aquitaine
Gustave Roussy ( Site 1103), Villejuif, Ile-de-France
Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1104), Nantes, Pays-de-la-Loire
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1102), Marseille, Provence-Alpes-Cote-d Azur
CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes
Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Site 1141), Münster, Nordrhein-Westfalen
Aghia Sophia Children's Hospital-First Department of Pediatrics, National and Kapodistrian Universi ( Site 1797), Athens, Attiki
Semmelweis Egyetem ( Site 1838), Budapest, Not set
Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set
Sheba Medical Center ( Site 1675), Ramat Gan, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori-Pediatric Oncology ( Site 1552), Milan, Lombardia
Ospedale Pediatrico Bambino Gesù IRCCS-Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica ( Site 1553), Rome, Roma
Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set
Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set
Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set
Narodny ustav detskych chorob ( Site 1592), Bratislava, Bratislavsky Kraj
Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona
Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De
Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set
Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan
National Taiwan University Hospital ( Site 1983), Taipei, Not set
Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set
Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set
Ege Universitesi Hastanesi ( Site 1963), İzmir, Not set
Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England
University College London Hospital ( Site 1350), London, London, City Of
Royal Marsden Hospital (Sutton)-Drug Development Unit ( Site 1347), Sutton., Surrey
University Hospital of Wales ( Site 1346), Cardiff, Not set
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Recruiting
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.
Epcoritamab is an investigational drug being developed for treating particip... Read More
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.
Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.
Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Hospital Privado Universitario De Córdoba /ID# 274457, Córdoba, Cordoba +25 locations
Hospital Privado Universitario De Córdoba /ID# 274457, Córdoba, Cordoba
Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390, Buenos Aires, Not set
Hospital Británico de Buenos Aires /ID# 274419, Buenos Aires, Not set
Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288, Graz, Steiermark
Universitair Ziekenhuis Brussel /ID# 273403, Jette, Bruxelles-Capitale
Centre Hospitalier Epicura - site d'Hornu /ID# 273406, Boussu, Hainaut
Grand Hôpital De Charleroi - Notre Dame /ID# 273728, Charleroi, Hainaut
Helora /ID# 273726, La Louvière, Hainaut
Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 273729, Genk, Limburg
Vitaz /Id# 273408, Sint-Niklaas, Oost-Vlaanderen
Cross Cancer Institute /ID# 271504, Edmonton, Alberta
Health Sciences North /ID# 274738, Sudbury, Ontario
Evangelismos Hospital /ID# 272736, Athens, Attiki
General Hospital of Athens Laiko /ID# 272758, Athens, Attiki
Metaxa Cancer Hospital Of Piraeus /ID# 273623, Piraeus, Attiki
University General Hospital of Alexandroupoli /ID# 272737, Alexandroupoli, Evros
University Hospital of Ioannina /ID# 272739, Ioannina, Not set
Papageorgiou General Hospital /ID# 272735, Thessaloniki, Not set
General Hospital Of Thessaloniki G. Papanikolaou /ID# 275323, Thessaloniki, Not set
Tel Aviv Sourasky Medical Center /ID# 271615, Tel Aviv, Tel-Aviv
Rabin Medical Center /ID# 271614, Petah Tikva, Not set
Complejo Hospitalario Universitario A Coruña /ID# 272040, A Coruña, A Coruna
Hospital Universitario Reina Sofia /ID# 272051, Córdoba, Cordoba
Hospital Universitario de Valme /ID# 272050, Seville, Sevilla
Hospital de Manises /ID# 272046, Manises, Valencia
Hospital Universitario Nuestra Señora de Candelaria /ID# 272413, Santa Cruz de Tenerife, Not set
Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Study of Out of Specification for Tisagenlecleucel
Recruiting
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated. Read Less
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
05/05/2025
Locations: Novartis Investigative Site, Hamilton, Ontario +52 locations
Novartis Investigative Site, Hamilton, Ontario
Novartis Investigative Site, Ottawa, Ontario
Novartis Investigative Site, Toronto, Ontario
Novartis Investigative Site, Toronto, Ontario
Novartis Investigative Site, Montreal, Quebec
Novartis Investigative Site, Quebec, Not set
Novartis Investigative Site, Nagoya-city, Aichi
Novartis Investigative Site, Nagoya, Aichi
Novartis Investigative Site, Toon city, Ehime
Novartis Investigative Site, Fukuoka city, Fukuoka
Novartis Investigative Site, Gifu-city, Gifu
Novartis Investigative Site, Sapporo city, Hokkaido
Novartis Investigative Site, Sapporo, Hokkaido
Novartis Investigative Site, Kobe, Hyogo
Novartis Investigative Site, Nishinomiya, Hyogo
Novartis Investigative Site, Tsukuba, Ibaraki
Novartis Investigative Site, Kanazawa, Ishikawa
Novartis Investigative Site, Kita-gun, Kagawa
Novartis Investigative Site, Yokohama-city, Kanagawa
Novartis Investigative Site, Kyoto-city, Kyoto
Novartis Investigative Site, Tsu-city, Mie
Novartis Investigative Site, Sendai city, Miyagi
Novartis Investigative Site, Matsumoto, Nagano
Novartis Investigative Site, Nagasaki-city, Nagasaki
Novartis Investigative Site, Yufu, Oita
Novartis Investigative Site, Kurashiki, Okayama
Novartis Investigative Site, Okayama-city, Okayama
Novartis Investigative Site, Izumi-city, Osaka
Novartis Investigative Site, Izumisano-city, Osaka
Novartis Investigative Site, Osaka Sayama, Osaka
Novartis Investigative Site, Osaka-city, Osaka
Novartis Investigative Site, Osaka-city, Osaka
Novartis Investigative Site, Suita, Osaka
Novartis Investigative Site, Izumo-city, Shimane
Novartis Investigative Site, Hamamatsu, Shizuoka
Novartis Investigative Site, Bunkyo ku, Tokyo
Novartis Investigative Site, Bunkyo ku, Tokyo
Novartis Investigative Site, Bunkyo ku, Tokyo
Novartis Investigative Site, Bunkyo-ku, Tokyo
Novartis Investigative Site, Chuo ku, Tokyo
Novartis Investigative Site, Fuchu, Tokyo
Novartis Investigative Site, Minato-ku, Tokyo
Novartis Investigative Site, Setagaya-ku, Tokyo
Novartis Investigative Site, Shinjuku-ku, Tokyo
Novartis Investigative Site, Aomori, Not set
Novartis Investigative Site, Chiba, Not set
Novartis Investigative Site, Hiroshima, Not set
Novartis Investigative Site, Kumamoto, Not set
Novartis Investigative Site, Kyoto, Not set
Novartis Investigative Site, Niigata, Not set
Novartis Investigative Site, Osaka, Not set
Novartis Investigative Site, Saitama, Not set
Novartis Investigative Site, Wakayama, Not set
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: UACC Arizona, Tucson, Arizona +175 locations
UACC Arizona, Tucson, Arizona
University of California San Francisco, San Francisco, California
University of California Los Angeles (UCLA), Santa Monica, California
Boca Raton Cancer Research Medical Center, Plantation, Florida
University of Chicago, Chicago, Illinois
Robert H. Lurie Comprehensive Cancer Center/Northwestern University, Chicago, Illinois
Norton Cancer Institute, Louisville, Kentucky
Dana Farber Cancer Institute, Boston, Massachusetts
Tufts Medical Center, Boston, Massachusetts
Lahey Clinic, Burlington, Massachusetts
University of Massachusetts Medical School, Worcester, Massachusetts
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Clinical Research Alliance, Lake Success, New York
New York Presbyterian Hospital/ Cornell Medical College, New York, New York
Stony Brook University Hospital, Stony Brook, New York
Gabrail Cancer Center, Canton, Ohio
Cleveland Clinic Foundation, Cleveland, Ohio
University Hospitals Seidman Cancer Center, Cleveland, Ohio
University of Oklahoma, Oklahoma City, Oklahoma
Greenville Hospital System, Greenville, South Carolina
MD Anderson, Houston, Texas
Swedish Cancer Institute, Seattle, Washington
Virginia Mason Hospital & Medical Center, Seattle, Washington
St. Vincent's Hospital Sydney, Darlinghurst, New South Wales
Liverpool Hospital, Ingham Institute of Medical Research, Liverpool, New South Wales
Calvary Mater Newcastle Hospital, Waratah, New South Wales
Icon Cancer Care, South Brisbane, Queensland
Royal Adelaide Hospital, Adelaide, South Australia
Ashford Cancer Centre, Kurralta Park, South Australia
Monash Medical Centre, Clayton, Victoria
Epworth Hospital, East Melbourne, Victoria
St. Vincent's Melbourne, Fitzroy, Victoria
The Alfred Hospital, Melbourne, Victoria
Fiona Stanley Hospital, Murdoch, Western Australia
Medical University of Graz, Graz, Not set
Medizinische Universität Innsbruck für Innere Medizin, Innsbruck, Not set
LKH Leoben Department for Haemato-Oncology, Leoben, Not set
Akh Linz Innere Med III - Zentrum für Hämatologie und med. Onkologie, Linz, Not set
Krankenhaus Barmherzigen Schwestern Linz, Linz, Not set
Krankenhaus der Elisabethinen Linz GmbH, Linz, Not set
Uni. Klinik für Innere Medizin III Universitätsklinikum der PMU LKH Salzburg, Salzburg, Not set
Medical University of Vienna (MUW) Department of Medicine I, Vienna, Not set
Univ. General Hospital Hietzing, Vienna, Not set
Ziekenhuis Netwerk Antwerpen, Antwerpen, Not set
AZ Sint-Jan, Bruges, Not set
Institut Jules Bordet, Brussels, Not set
Cliniques Universitaires Saint-Luc, Brussels, Not set
UZ Gent, Gent, Not set
CH Jolimont, La Louviere, Not set
AZ Delta, Roeselare, Not set
H-Hartziekenhuis Roeselare-Menen, Roeselare, Not set
University Hospital for Active Treatment Dr. Georgi Stranski, Pleven, Not set
University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Not set
Specialized Hospital for Active Treatment of Haematological Diseases EAD, Sofia, Not set
Princess Margaret Cancer Centre, Toronto, Ontario
Sir Mortimer B Davis Jewish General Hospital/McGill University, Montreal, Quebec
CHU Lyon Sud, Pierre-Bénite, Lyon
Centre Hospitalier Universitaire Henri Mondor, Créteil, Not set
Unite Hemopathies Lymphoides Chu Henri Mondor, Créteil, Not set
Chu Dijon-Bourgogne - Hematologie Clinique, Dijon, Not set
Hospitalier de la Rochelle-Ré-Aunis, La Rochelle, Not set
CHRU de Lille - Hopital Claude-Huriez, Lille, Not set
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, Not set
CHU Montpellier, Montpellier, Not set
Hostpial Saint Louis - CIRCO (Centre d'Investigations et de Recherche Clinique en Oncologie), Paris, Not set
Hôpital Necker Service d'Hématologie Adult, Paris, Not set
Pitié-Salpêtrière Hospital, Paris, Not set
Centre Henri Becquerel, Rouen, Not set
Uniklinik Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Not set
HELIOS Klinikum Bad Saarow, Bad Saarow, Not set
Charite Universitatsmedizin Berlin (Benjamin Franklin Campus), Berlin, Not set
Charite Universitatsmedizin Berlin (Virchow Campus), Berlin, Not set
Ev. Diakonie-Krankenhaus gGmbH, Bremen, Not set
Gemeinschaftspraxis Haematologie and Onkologie-Dresden, Dresden, Not set
Martin-Luther-University Halle-Wittenberg Department of Oncology, Halle, Not set
Medizinische Hochschule, Hannover, Not set
Universität Heidelberg Medizinische Klinik V Hämatologie, Onkologie und Rheumatologie, Heidelberg, Not set
Klinikum Kempten Klinik für Innere Medizin III - Hämatologie, Onkologie und Palliativmedizin, Koln, Not set
Klinikum Leverkusen, Leverkusen, Not set
Klinikum Ludwigshafen, Ludwigshafen, Not set
Rotkreuzklinikum München, Muenchen, Not set
Klinikum Nürnberg Nord, Nuernberg, Not set
Haematology Department and HCT Unit G.Papanicolaou Hospital, Exochi, Thessaloniki
Hematology Clinic,General Hospital of Athens,G. Gennimatos, Athens, Not set
National & Kapodistrian University of Athens, Laiko General Hospital, Athens, Not set
Hematology Department Laiko General Hospital, Athens, Not set
Second Depth of Internal Medicine, Attiko University Hospital, Athens, Not set
National & Kapodistrian University of Athens, Attiko University Hospital, Chaidari, Not set
Department of clinical hematology ,university hospital Ioannina, Ioánnina, Not set
University of Patras Medical School, Patras, Not set
Semmelweis Egyetem Általános Orvosi Kar, Budapest, Not set
Országos Onkológiai Intézet "A" Belgyógyászati Onkológiai Osztály, Budapest, Not set
Semmelweis University Department of Medicine and Oncology, Budapest, Not set
Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Not set
Pécsi Tudományegyetem, ÁOK, I. számú Belgyógyászati Klinika, Pécs, Not set
Veszprém Megyei Csolnoky Ferenc Kórház, Veszprém, Not set
CSolnoky ferenc Hospital, Veszprém, Not set
Regional Cancer Centre, IGIMS, Patna, Bihar
SRM Institutes for Medical Science, Vadapalani, Chennai
Rajiv Gandhi Cancer Hospital, New Delhi, Delhi
Regional Cancer Centre, Thiruvananthapuram, Kerala
Prince Aly Khan Hospital, Mumbai, Maharashtra
Jaslok Hospital and Research Centre, Mumbai, Maharashtra
Deenanath Mangeshkar Hospital, Pune, Maharashtra
Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha
Dayanand Medical College and Hospital, Ludhiāna, Punjab
Cancer Institute (WIA), Chennai, Tamil Nadu
Saveetha Medical College Hospital, Chennai, Tamil Nadu
G. Kuppu Swamy Naidu Hospital, Coimbatore, Tamil Nadu
Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu
King George's Medical University (KGMU), Lucknow, Uttar Pradesh
Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal
Netaji Subhas Chandra Bose Cancer Research Hospital, Kolkata, West Bengal
TATA Memorial Centre, Kolkata, West Bengal
Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal
IRCH, All India Institute of Medical Sciences, Delhi, Not set
Dr. B.R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences, New Delhi, Not set
Hematology-Soroka, Beer Sheva, Not set
Rambam Healthcare Campus, Haifa, Not set
Wolfson MC, Holon, Not set
Hadassah Medical Center, Jerusalem, Not set
Rabin Medical Center, Petach Tikva, Not set
Assuta Medical Center, Tel Aviv, Not set
TLV Sorasky Medical Center, Tel Aviv, Not set
Sheba Medical Center, Tel Hashomer, Not set
Instituto di Ematologia Seragnoli Pad 8 Universita di Bologna, Bologna, Not set
SODc Ematologica ,AOU Careggi, Florence, Not set
AOU Maggiore della Carità SCDU Ematologia, Florence, Not set
Hematology-Oncology & Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Not set
SCDU Ematologia, Division of Hematology, Dept. of Translational Medicine, Universita del Piemonte Orientale, Novara, Not set
Fondazione Policlinico Universitario A. Gemelli, Rome, Not set
Azienda Ospedaliero-Universitaria Senese, Siena, Not set
Città della Salute e della Scienza di Torino, Torino, Not set
VUMc (Vrije Universiteit Amsterdam), Amsterdam, Not set
LUMC (leidse universitair medisch centrum), Leiden, Not set
North Shore Hospital, Auckland, Not set
Christchurch Hospital, Christchurch, Not set
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza, Wrocław, Radeckiego
Szpitale Wojewódzkie w Gdyni, Gdyńskie Centrum onkologii, Gdynia, Not set
MCM (Małopolskie Centrum Medyczne), Krakow, Not set
Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica, Not set
Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Not set
Hematology Department St John's Cancer Centre, Lublin, Not set
Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa, Olsztyn, Not set
Instytut Hematologii i Transfuzjologii, Warszawa, Not set
Centrum Onkologii- Insytut Im. Marii Skłodowskiej-Curie Klinika Nowotworow Ukladu Chlonnego, Warszawa, Not set
Maria Sklodowska Curie National Research Institute, Warszawa, Not set
Memorial Provincial Specialist Hospital in Lodz, Łódź, Not set
Institut za onkologiju i radiologiju Srbije, Belgrade, Not set
Klinicko Bolnick Centar Zemun Odeljenje hematologije, Belgrade, Not set
Klinički centar Srbije Klinika za hematologiju, Belgrade, Not set
Kliničko bolnički centar Zvezdara, Belgrade, Not set
Klinički centar Niš Klinika za hematologiju, Nis, Not set
Institut za onkologiju Vojvodine, Sremska Kamenica, Not set
Hospitla Universitari Germans Trias i Pujol - ICO, Badalona, Not set
Hospital University Vall d'Hebron, Barcelona, Not set
Hospital Clinic i Provincial de Barcelona, Barcelona, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital de Son Llàtzer, Palma de Mallorca, Not set
Clínica Universidad De Navarra, Pamplona, Not set
Hospital Universitario de Salamanca, Salamanca, Not set
Hospital Universitario Virgen del Rocio, Sevilla, Not set
Gloucestershire Royal Hospital, Gloucester, Gloucestershire
Southampton University Hospital, Southampton, Hampshire
Royal Marsden Hospital, Sutton, London
Northwick Park Hospital, Harrow, Middlesex
Leeds Teaching Hospitals NHS Trust, Leeds, Yorkshire
Addenbrooke's Hospital Cambridge, Cambridge, Not set
Royal Liverpool University Hospital, Liverpool, Not set
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set
King's College Hospital, London, Not set
Princess Royal University Hospital (PRUH), London, Not set
Guy's and St Thomas' NHS Foundation Trust, London, Not set
The Christie NHS Foundation Trust, Manchester, Not set
Oxford University Hospitals NHS Trust Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, Not set
Derriford Hospital, Plymouth, Not set
Conditions: Diffuse Large B-cell Lymphoma
1 - 10 of 10